AAAAAA

   
Results: 1-10 |
Results: 10
Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models
Authors: Liu, M Bishop, WR Nielsen, LL Bryant, MS Kirschmeier, P
Citation: M. Liu et al., Orally bioavailable farnesyltransferase inhibitors as anticancer agents intransgenic and xenograft models, METH ENZYM, 333, 2001, pp. 306-318
Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches
Authors: Wang, LQ Wu, Q Qiu, P Mirza, A McGuirk, M Kirschmeier, P Greene, JR Wang, YL Pickett, CB Liu, SX
Citation: Lq. Wang et al., Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches, J BIOL CHEM, 276(47), 2001, pp. 43604-43610
The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M or G(1) pause in sensitive human tumor cell lines
Authors: Ashar, HR James, L Gray, K Carr, D McGuirk, M Maxwell, E Black, S Armstrong, L Doll, RJ Taveras, AG Bishop, WR Kirschmeier, P
Citation: Hr. Ashar et al., The farnesyl transferase inhibitor SCH 66336 induces a G(2) -> M or G(1) pause in sensitive human tumor cell lines, EXP CELL RE, 262(1), 2001, pp. 17-27
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia
Authors: Peters, DG Hoover, RR Gerlach, MJ Koh, EY Zhang, HY Choe, K Kirschmeier, P Bishop, WR Daley, GQ
Citation: Dg. Peters et al., Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia, BLOOD, 97(5), 2001, pp. 1404-1412
Tricyclic farnesyl protein transferase inhibitors - Antitumor activity andeffects on protein prenylation
Authors: Bishop, WR Pai, JJK Armstrong, L Dalton, MB Doll, RJ Taveras, A Njoroge, G Sinensky, M Zhang, F Liu, M Kirschmeier, P
Citation: Wr. Bishop et al., Tricyclic farnesyl protein transferase inhibitors - Antitumor activity andeffects on protein prenylation, CANC DRUG, 8, 2001, pp. 87-101
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules
Authors: Ashar, HR James, L Gray, K Carr, D Black, S Armstrong, L Bishop, WR Kirschmeier, P
Citation: Hr. Ashar et al., Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules, J BIOL CHEM, 275(39), 2000, pp. 30451-30457
A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
Authors: Adjei, AA Erlichman, C Davis, JN Cutler, DL Sloan, JA Marks, RS Hanson, LJ Svingen, PA Atherton, P Bishop, WR Kirschmeier, P Kaufmann, SH
Citation: Aa. Adjei et al., A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity, CANCER RES, 60(7), 2000, pp. 1871-1877
Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity
Authors: Njoroge, FG Vibulbhan, B Bishop, WR Kirschmeier, P Bryant, MS Nomeir, AA Liu, M Doll, RJ Girijavallabhan, VM Ganguly, AK
Citation: Fg. Njoroge et al., Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity, BIO MED CH, 7(5), 1999, pp. 861-867
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice
Authors: Liu, M Bryant, MS Chen, JP Lee, SN Yaremko, B Li, ZJ Dell, J Lipari, P Malkowski, M Prioli, N Rossman, RR Korfmacher, WA Nomeir, AA Lin, CC Mallams, AK Doll, RJ Catino, JJ Girijavallabhan, VM Kirschmeier, P Bishop, WR
Citation: M. Liu et al., Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice, CANC CHEMOT, 43(1), 1999, pp. 50-58
Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities
Authors: Taveras, AG Deskus, J Chao, JP Vaccaro, CJ Njoroge, FG Vibulbhan, B Pinto, P Remiszewski, S del Rosario, J Doll, RJ Alvarez, C Lalwani, T Mallams, AK Rossman, RR Afonso, A Girijavallabhan, VM Ganguly, AK Pramanik, B Heimark, L Bishop, WR Wang, L Kirschmeier, P James, L Carr, D Patton, R Bryant, MS Nomeir, AA Liu, M
Citation: Ag. Taveras et al., Identification of pharmacokinetically stable 3,10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities, J MED CHEM, 42(14), 1999, pp. 2651-2661
Risultati: 1-10 |